A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of MG-ZG122 Humanized Monoclonal Antibody Injection in Adult Subjects With Moderate-to-Severe Asthma to Evaluate Efficacy and Safety
Latest Information Update: 18 Jul 2025
At a glance
- Drugs MGZG-122 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Shanghai Mabgeek Biotech
Most Recent Events
- 18 Jul 2025 New trial record